Glycosaminoglycans in Neurodegenerative Diseases

Adv Exp Med Biol. 2021:1325:189-204. doi: 10.1007/978-3-030-70115-4_9.

Abstract

Glycosaminoglycans (GAGs) are linear polysaccharides that consist of alternating disaccharides sequences of uronic acids and/or galactose hexamino sugars most of which are sulfated. GAGs are ubiquitously expressed on the cell surface, in the intracellular milieu and in the extracellular matrix of all animal cells. Thus, GAGs exhibit many essential roles in a variety of physiological and pathological processes. The targets of GAGs are GAG-binding proteins and related proteins that are of significant interest to both the academic community and in the pharmaceutical industry. In this review, the structures of GAGs, their binding proteins, and analogs are presented that further the development of GAGs and their analogs for the treatment of neurodegenerative diseases agents.

Keywords: Alzheimer’s disease; Glycosaminoglycans; Heparan sulfate; Neurodegenerative diseases; Parkinson’s disease.

Publication types

  • Review

MeSH terms

  • Animals
  • Glycosaminoglycans*
  • Neurodegenerative Diseases* / drug therapy
  • Polysaccharides
  • Sulfates

Substances

  • Glycosaminoglycans
  • Polysaccharides
  • Sulfates